|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
DE3211934A1
(de)
*
|
1982-03-31 |
1983-10-13 |
Hoechst Ag, 6230 Frankfurt |
Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
|
|
KR890002631B1
(ko)
|
1984-10-04 |
1989-07-21 |
몬산토 캄파니 |
생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
DE69632684T2
(de)
|
1995-06-27 |
2005-06-09 |
Takeda Pharmaceutical Co. Ltd. |
Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
|
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
|
ES2221019T3
(es)
|
1996-10-31 |
2004-12-16 |
Takeda Chemical Industries, Ltd. |
Preparacion de liberacion mantenida.
|
|
EP0946169B1
(en)
|
1996-12-20 |
2003-02-26 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
AU2003284217A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
KR20080073749A
(ko)
*
|
2005-11-14 |
2008-08-11 |
버텍스 파마슈티칼스 인코포레이티드 |
전압 개폐 이온 채널 조절제로서 유용한 퀴나졸린
|
|
US20100227872A1
(en)
|
2007-05-03 |
2010-09-09 |
Mark Ian Kemp |
Pyrazine derivatives
|
|
BR112014009102A2
(pt)
|
2011-10-26 |
2017-04-18 |
Pfizer Ltd |
compostos químicos
|
|
WO2013114250A1
(en)
|
2012-02-03 |
2013-08-08 |
Pfizer Inc. |
Benziimidazole and imidazopyridine derivatives as sodium channel modulators
|
|
KR102226587B1
(ko)
|
2013-01-31 |
2021-03-11 |
버텍스 파마슈티칼스 인코포레이티드 |
나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
|
|
CN105026373B
(zh)
|
2013-01-31 |
2018-03-30 |
沃泰克斯药物股份有限公司 |
作为钠通道调节剂的吡啶酮酰胺
|
|
BR112015018284B1
(pt)
|
2013-01-31 |
2023-03-07 |
Vertex Pharmaceuticals Incorporated |
Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica
|
|
JP6337109B2
(ja)
|
2013-07-19 |
2018-06-06 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
ナトリウムチャネルの調節剤としてのスルホンアミド
|
|
SG11201604477SA
(en)
|
2013-12-13 |
2016-07-28 |
Vertex Pharma |
Prodrugs of pyridone amides useful as modulators of sodium channels
|
|
TW202140422A
(zh)
*
|
2014-10-06 |
2021-11-01 |
美商維泰克斯製藥公司 |
囊腫纖維化症跨膜傳導調節蛋白之調節劑
|
|
KR102714561B1
(ko)
|
2017-05-16 |
2024-10-10 |
버텍스 파마슈티칼스 인코포레이티드 |
나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
|
|
AU2018300150A1
(en)
|
2017-07-11 |
2020-01-30 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
US20190343817A1
(en)
|
2018-02-12 |
2019-11-14 |
Vertex Pharmaceuticals Incorporated |
Method of treating pain
|
|
AU2019302534B2
(en)
|
2018-07-09 |
2024-10-03 |
Lieber Institute, Inc. |
Pyridazine compounds for inhibiting NaV1.8
|
|
SG11202100130QA
(en)
|
2018-07-09 |
2021-02-25 |
Lieber Institute Inc |
Pyridine carboxamide compounds for inhibiting nav1.8
|
|
WO2020092187A1
(en)
|
2018-11-02 |
2020-05-07 |
Merck Sharp & Dohme Corp. |
2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
|
|
GEAP202315648A
(en)
|
2018-11-02 |
2023-07-25 |
Merck Sharp & Dohme Llc |
2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
|
|
WO2020146682A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
WO2020219867A1
(en)
|
2019-04-25 |
2020-10-29 |
Vertex Pharmaceuticals Incorporated |
Pyridone amide co-crystal compositions for the treatment of pain
|
|
MA56398A
(fr)
|
2019-06-27 |
2022-05-04 |
Glaxosmithkline Ip Dev Ltd |
Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
|
|
TW202115038A
(zh)
|
2019-08-19 |
2021-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
|
|
PH12022551379A1
(en)
|
2019-12-06 |
2023-05-03 |
Vertex Pharma |
Substituted tetrahydrofurans as modulators of sodium channels
|
|
CN115697327A
(zh)
|
2020-06-17 |
2023-02-03 |
默沙东有限责任公司 |
作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
|
|
US11802122B2
(en)
|
2020-06-17 |
2023-10-31 |
Merck Sharp & Dohme Llc |
2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
|
|
KR20230026404A
(ko)
|
2020-06-17 |
2023-02-24 |
머크 샤프 앤드 돔 엘엘씨 |
Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
|
|
CN114591293B
(zh)
*
|
2020-12-07 |
2026-06-02 |
成都康弘药业集团股份有限公司 |
作为Nav1.8抑制剂的并环化合物及其用途
|